TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

被引：20
|
作者：
Manns, M. [1 ]
Muir, A. [2 ]
Adda, N. [3 ]
Jacobson, I. [4 ]
Afdhal, N. [5 ]
Heathcote, J. [6 ]
Zeuzem, S. [7 ]
Reesink, H. [8 ]
Terrault, N. [9 ]
Bsharat, M. [3 ]
George, S. [3 ]
McHutchison, J. [2 ]
Di Bisceglie, A. [10 ]
机构：
[1] Hannover Med Sch, D-3000 Hannover, Germany
[2] Duke Univ, Med Ctr, Durham, NC 27706 USA
[3] Vertex Pharmaceut, Cambridge, MA USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[6] Univ Toronto, Toronto, ON, Canada
[7] Univ Frankfurt, Frankfurt, Germany
[8] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[9] Univ Calif San Francisco, San Francisco, CA 94143 USA
[10] St Louis Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF HEPATOLOGY | 2009年 / 50卷
关键词：
D O I：
10.1016/S0168-8278(09)61046-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1044
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [31] EXTENDED TREATMENT WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY CAN SUPPRESS THE RELAPSE RATE AFTER TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS WITH LATE VIRAL RESPONSE
    Oze, Tsugiko
    Hiramatsu, Naoki
    Yakushijin, Takayuki
    Kurokawa, Mika
    Igura, Takumi
    Mochizuki, Kiyoshi
    Imanaka, Kazuho
    Yamada, Akira
    Oshita, Masahide
    Hagiwara, Hideki
    Mita, Eiji
    Ito, Toshifumi
    Inui, Yoshiaki
    Hijioka, Taizo
    Yoshihara, Harumasa
    Hayashi, Eijirou
    Inoue, Atsuo
    Imai, Yasuharu
    Kato, Michio
    Yoshida, Yuichi
    Tatsumi, Tomohide
    Ohkawa, Kazuyoshi
    Kiso, Shinichi
    Kanto, Tatsuya
    Kasahara, Akinori
    Tamura, Shinji
    Tokehara, Tetsuo
    Hayashi, Norio
    HEPATOLOGY, 2008, 48 (04) : 853A - 854A
  • [32] Interferon alfa-2a in combination with ribavirin and amantadine (triple therapy) in hepatitis C patients with previous non-response or relapse to interferon alfa and ribavirin combination therapy.
    Reichard, O
    Lindahl, K
    Schvarcz, R
    Uhnoo, I
    Shev, S
    Carlsson, T
    Wejstal, R
    HEPATOLOGY, 1999, 30 (04) : 372A - 372A
  • [33] Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    Buti, M
    Sanchez-Avila, F
    Lurie, Y
    Stalgis, C
    Valdés, A
    Martell, M
    Esteban, R
    HEPATOLOGY, 2002, 35 (04) : 930 - 936
  • [34] Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment
    Muir, Andrew J.
    Poordad, Fred
    Adda, Nathalie
    Shiffman, Mitchell L.
    Berg, Thomas
    Ferenci, Peter
    Heathcote, E. Jenny
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    Reesink, Henk W.
    Dusheiko, Geoffrey M.
    Martin, Emily C.
    Alexanderian, David
    George, Shelley
    McHutchison, John
    GASTROENTEROLOGY, 2010, 138 (05) : S782 - S783
  • [35] VIRAL RESPONSES IN AFRICAN-AMERICANS, LATINOS AND CAUCASIANS IN THE US PHASE 2 STUDY (PROVE1) OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAME GENOTYPE 1-INFECTED SUBJECTS WITH HEPATITIS C
    Muir, Andrew J.
    Lawitz, Eric J.
    McHutchison, John G.
    Gordon, Stuart C.
    Jacobson, Ira M.
    Adiwijaya, Bambang S.
    Bengtsson, Leif
    McNair, Lindsay
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2008, 48 (04) : 1131A - 1132A
  • [36] HIGH VS STANDARD DOSE OF RIBAVIRIN PLUS PEGINTERFERON-ALFA-2A IN CHRONIC HEPATITIS C, GENOTYPE 3 AND HIGH VIRAL LOAD. FINAL RESULTS OF THE DARGEN-3 STUDY
    Fernandez Rodriguez, C. M.
    Masnou, H.
    Morillas, R.
    Navarro, J. M.
    Barcena, R.
    Hernandez, J. M.
    Martin Martin, L.
    Garcia Poyato, A.
    Miquel Planas, M.
    Jorquera, F.
    Casanova, T.
    Romero-Gomez, M.
    Salmeron, J.
    Calleja, J. L.
    Sola, R.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S437 - S437
  • [37] Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study
    Moog, Gero
    Mauss, Stefan
    Hueppe, Dietrich
    Spengler, Ulrich
    Schott, Eckart
    Eisenbach, Christoph
    Schober, Andreas
    Heyne, Renate
    Jung, Maria-Christina
    Teuber, Gerlinde
    Doss, Margareta Frank
    Roessle, Martin
    Pape, Stefan
    Schuchmann, Marcus
    Alshuth, Ulrich
    Buggisch, Peter
    GASTROENTEROLOGY, 2013, 144 (05) : S980 - S980
  • [38] Hepatitis C virus core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirin
    Buti, M
    Mendez, C
    Schaper, M
    Sauleda, S
    Valdes, A
    Rodriguez-Frias, F
    Jardi, R
    Esteban, R
    JOURNAL OF HEPATOLOGY, 2004, 40 (03) : 527 - 532
  • [39] The role of cholesterol on sustained virological response (SVR) in the treatment of genotype-1 infected hepatitis C (cHC) patients with peginterferon Alfa-2a (PEG) and ribavirin (RBV)
    Mauss, Stefan
    Zehnter, Elmar
    Hueppe, Dietrich
    Kaiser, Stephan
    Becker, Klaus
    Lutz, Thomas
    Heyne, Renate
    John, Christine
    Moog, Gero
    Schober, Andreas
    Pfaff, Rainer
    Zipf, Andreas
    Racky, Stefan A.
    Lohmeyer, Jueregn
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Witthoeft, Thomas
    Alshuth, Ulrich
    GASTROENTEROLOGY, 2008, 134 (04) : A829 - A829
  • [40] The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
    Simara Artico
    Karine Medeiros Amaral
    Candice Beatriz Treter Gonçalves
    Paulo Dornelles Picon
    BMC Infectious Diseases, 12
12345